Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)

1

Introduction

00:00 • 2min

2

Is There a Next Line Therapy for Osmurtenib?

01:41 • 2min

3

EJFR-X-on-20 Infections - What's the Difference?

04:05 • 2min

4

IOs in EJFR Mutant Disease?

06:19 • 2min

5

Is Ami Vantanib a Better Choice?

08:25 • 3min

6

IBI, Do You Want to Continue?

11:29 • 3min

7

TDXD Versus TDM1 in the First Line Setting?

14:49 • 3min

8

TDXD in Lung Cancer?

18:03 • 2min

9

Is Immunotherapy a Monotherapy for Pneumonitis?

19:48 • 2min

10

Is There a Second-Line Therapy for BRAF V600E?

21:30 • 2min

11

Is There a KRS Inhibitor in Colorectal Cancer?

23:36 • 3min

12

Is CNS Monitoring Really Important?

26:29 • 2min

13

Adjuvant I.O.

28:07 • 2min

14

PDL1 High - Is There a Benefit?

30:16 • 5min

15

Is There a PD-1 Level in Adipose Tumors?

34:52 • 3min

16

How Long Would You Wait?

37:45 • 3min

17

Adora Trials

40:20 • 4min

18

Immunotherapy for Non-Smoking Lung Cancer

44:27 • 3min

19

Lung Cancer - Monotherapy vs Chemotherapy?

46:58 • 5min

20

Is There a Difference Between PD-1 and PD-L-1?

51:59 • 2min

21

Pneumonitis With Antibiotic Drug Conjugates

54:28 • 5min